The opportunity to redefine the treatment of major diseases is what drives everyone at Vertex. Our development portfolio represents the fruit of these efforts. Spend some time here and look around. Click on the pipeline chart to get information on our development programs and links to selected published articles. Go further and see how, just maybe, disease challenges may be overcome with innovation.

VX-500
(HCV Infection)

VX-500 is a second-generation HCV protease inhibitor. Vertex has initiated dosing in a Phase 1a clinical trial of VX-500. The trial will evaluate single, escalating doses of VX-500 in healthy volunteers. Pending results from the Phase 1a trial, Vertex expects to initiate in mid-2008 a Phase 1b trial of VX-500 in HCV patients.